Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

ADMP

Adamis Pharmaceuticals (ADMP)

Adamis Pharmaceuticals Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ADMP
FechaHoraFuenteTítuloSímboloCompañía
07/02/202208:17GlobeNewswire Inc.Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19NASDAQ:ADMPAdamis Pharmaceuticals Corporation
12/01/202203:07TipRanksAdamis Pharma Updates 1 Key Risk FactorNASDAQ:ADMPAdamis Pharmaceuticals Corporation
10/01/202215:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
10/01/202206:30GlobeNewswire Inc.Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19NASDAQ:ADMPAdamis Pharmaceuticals Corporation
03/12/202116:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
01/12/202106:30GlobeNewswire Inc.Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™NASDAQ:ADMPAdamis Pharmaceuticals Corporation
23/11/202113:39GlobeNewswire Inc.Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing RequirementsNASDAQ:ADMPAdamis Pharmaceuticals Corporation
22/11/202116:16Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
22/11/202115:47GlobeNewswire Inc.Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateNASDAQ:ADMPAdamis Pharmaceuticals Corporation
19/11/202114:34GlobeNewswire Inc.Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business UpdateNASDAQ:ADMPAdamis Pharmaceuticals Corporation
18/10/202106:30GlobeNewswire Inc.Adamis Receives FDA Approval for ZIMHINASDAQ:ADMPAdamis Pharmaceuticals Corporation
06/10/202115:49Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
04/10/202106:30GlobeNewswire Inc.Adamis Announces Appointment of Meera Desai, Ph.D., to Board of DirectorsNASDAQ:ADMPAdamis Pharmaceuticals Corporation
02/09/202106:30GlobeNewswire Inc.Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19NASDAQ:ADMPAdamis Pharmaceuticals Corporation
24/08/202115:05GlobeNewswire Inc.Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other EventsNASDAQ:ADMPAdamis Pharmaceuticals Corporation
24/08/202106:30GlobeNewswire Inc.Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s CellsNASDAQ:ADMPAdamis Pharmaceuticals Corporation
19/08/202106:30GlobeNewswire Inc.Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”NASDAQ:ADMPAdamis Pharmaceuticals Corporation
16/08/202115:42Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
04/08/202115:05GlobeNewswire Inc.Adamis Announces Agreement to Sell Portion of US Compounding BusinessNASDAQ:ADMPAdamis Pharmaceuticals Corporation
19/07/202115:05Business WireAdamis Announces Results of 2021 Annual Meeting of StockholdersNASDAQ:ADMPAdamis Pharmaceuticals Corporation
13/07/202107:28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
13/07/202107:00Business WireAdamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16thNASDAQ:ADMPAdamis Pharmaceuticals Corporation
01/07/202107:00Business Wire Adamis Sends Letter to Stockholders to Address Jerald A. Hammann’s Costly, Distracting and Misguided CampaignNASDAQ:ADMPAdamis Pharmaceuticals Corporation
28/06/202106:00Business WireAdamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19NASDAQ:ADMPAdamis Pharmaceuticals Corporation
14/06/202108:00Business WireAdamis Files Definitive Proxy Statement and Sends Letter to StockholdersNASDAQ:ADMPAdamis Pharmaceuticals Corporation
14/06/202105:03Edgar (US Regulatory)Proxy Statment - Contested Solicitations (definitive) (defc14a)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
11/06/202106:30GlobeNewswire Inc.Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19NASDAQ:ADMPAdamis Pharmaceuticals Corporation
09/06/202106:30GlobeNewswire Inc.Adamis Provides Update on ZIMHI™NASDAQ:ADMPAdamis Pharmaceuticals Corporation
07/06/202106:30GlobeNewswire Inc.Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19NASDAQ:ADMPAdamis Pharmaceuticals Corporation
02/06/202107:20Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
 Showing the most relevant articles for your search:NASDAQ:ADMP

Su Consulta Reciente